Avid Bioservices(CDMO) - 2024 Q4 - Annual Results

Exhibit 99.1 -- FY 2025 Revenue Guidance of Between $160 Million and $168 Million -- "The enhancements and expansion not only allow Avid to better serve its new and existing biotech customers but, importantly, enable the company to address the needs of large pharma as well. The expanded addressable market and improvements in the broader business environment have resulted in an increase in larger and later stage programs in our production pipeline. With respect to capacity, our utilization is expected to inc ...